<DOC>
	<DOCNO>NCT00151918</DOCNO>
	<brief_summary>The purpose study assess phosphate reduction control patient End Stage Renal Disease treat either lanthanum carbonate sevelamer hydrochloride</brief_summary>
	<brief_title>Efficacy Safety Lanthanum Carbonate Sevelamer Hydrochloride Patients Receiving Haemodialysis End Stage Renal Disease</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Sevelamer</mesh_term>
	<criteria>Patients receive haemodialysis ESRD Patients must receive haemodialysis chronic renal failure three time per week least previous 2 month Pregnant lactating woman Patients clinically significant uncontrolled concurrent illness , lifethreatening malignancy current multiple myeloma Patients HIV+ Patients significant bowel obstruction , active inflammatory bowel disease , GI motility disorder , history major GI surgery within last 6 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2007</verification_date>
</DOC>